Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

1.880 -0.180 (-8.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,924,795
Open 2.060
Bid (Size) 1.910 (1,000)
Ask (Size) 1.950 (3,100)
Prev. Close 2.060
Today's Range 1.852 - 2.070
52wk Range 0.8332 - 5.550
Shares Outstanding 38,245,287
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill

Performance

YTD
+63.5%
+63.5%
1 Month
-55.2%
-55.2%
3 Month
-45.5%
-45.5%
6 Month
+58.0%
+58.0%
1 Year
+22.9%
+22.9%

More News

Read More
News headline image
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Top movers in Thursday's session ↗
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
From Pyxis Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in September Investor and Industry Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
From Pyxis Oncology
Via GlobeNewswire

Frequently Asked Questions

Is Pyxis Oncology, Inc. - Common Stock publicly traded?
Yes, Pyxis Oncology, Inc. - Common Stock is publicly traded.
What exchange does Pyxis Oncology, Inc. - Common Stock trade on?
Pyxis Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pyxis Oncology, Inc. - Common Stock?
The ticker symbol for Pyxis Oncology, Inc. - Common Stock is PYXS on the Nasdaq Stock Market
What is the current price of Pyxis Oncology, Inc. - Common Stock?
The current price of Pyxis Oncology, Inc. - Common Stock is 1.880
When was Pyxis Oncology, Inc. - Common Stock last traded?
The last trade of Pyxis Oncology, Inc. - Common Stock was at 01/13/26 04:00 PM ET
What is the market capitalization of Pyxis Oncology, Inc. - Common Stock?
The market capitalization of Pyxis Oncology, Inc. - Common Stock is 71.90M
How many shares of Pyxis Oncology, Inc. - Common Stock are outstanding?
Pyxis Oncology, Inc. - Common Stock has 72M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.